Erica Lynn Bradshaw-Pierce1, Kendra M. Hasebroock, Andrea L. Merz, John J. Tentler2, S Gail Eckhardt2, Natalie J. Serkova
1Anesthesiology, University of Colorado Denver Health Sciences Program, Aurora, CO, USA; 2Medical Oncology, University of Colorado Denver Health Sciences Program
Quantitative DCE-MRI and PET endpoints were used to assess therapeutic efficacy of two different signal transduction modulators in a mouse model human cancer. Tumors responded well to one of the agents and only modestly to the other. We show utility of DCE-MRI and PET to evaluate the anti-angiogenic and metabolic activity of highly responsive tumors. Our data also shows that DCE-MRI and PET did not provide any indication of moderate therapeutic response, as our non-responsive agent managed to reduce tumor volume by 45% compared to control. Additionally, we found that the total tumor volume negatively correlates with Gd-uptake kinetics.